284 related articles for article (PubMed ID: 16137931)
1. Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.
Lazarenko OP; Rzonca SO; Suva LJ; Lecka-Czernik B
Bone; 2006 Jan; 38(1):74-84. PubMed ID: 16137931
[TBL] [Abstract][Full Text] [Related]
2. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation.
Lecka-Czernik B; Moerman EJ; Grant DF; Lehmann JM; Manolagas SC; Jilka RL
Endocrinology; 2002 Jun; 143(6):2376-84. PubMed ID: 12021203
[TBL] [Abstract][Full Text] [Related]
3. Bone is a target for the antidiabetic compound rosiglitazone.
Rzonca SO; Suva LJ; Gaddy D; Montague DC; Lecka-Czernik B
Endocrinology; 2004 Jan; 145(1):401-6. PubMed ID: 14500573
[TBL] [Abstract][Full Text] [Related]
4. Thiazolidinedione effects on glucocorticoid receptor-mediated gene transcription and differentiation in osteoblastic cells.
Johnson TE; Vogel R; Rutledge SJ; Rodan G; Schmidt A
Endocrinology; 1999 Jul; 140(7):3245-54. PubMed ID: 10385421
[TBL] [Abstract][Full Text] [Related]
5. β-catenin directly sequesters adipocytic and insulin sensitizing activities but not osteoblastic activity of PPARγ2 in marrow mesenchymal stem cells.
Rahman S; Czernik PJ; Lu Y; Lecka-Czernik B
PLoS One; 2012; 7(12):e51746. PubMed ID: 23272157
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.
Ali AA; Weinstein RS; Stewart SA; Parfitt AM; Manolagas SC; Jilka RL
Endocrinology; 2005 Mar; 146(3):1226-35. PubMed ID: 15591153
[TBL] [Abstract][Full Text] [Related]
7. Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders.
Nuttall ME; Patton AJ; Olivera DL; Nadeau DP; Gowen M
J Bone Miner Res; 1998 Mar; 13(3):371-82. PubMed ID: 9525337
[TBL] [Abstract][Full Text] [Related]
8. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways.
Moerman EJ; Teng K; Lipschitz DA; Lecka-Czernik B
Aging Cell; 2004 Dec; 3(6):379-89. PubMed ID: 15569355
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of PPARgamma prevents type I diabetic bone marrow adiposity but not bone loss.
Botolin S; McCabe LR
J Cell Physiol; 2006 Dec; 209(3):967-76. PubMed ID: 16972249
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells.
Gimble JM; Robinson CE; Wu X; Kelly KA; Rodriguez BR; Kliewer SA; Lehmann JM; Morris DC
Mol Pharmacol; 1996 Nov; 50(5):1087-94. PubMed ID: 8913339
[TBL] [Abstract][Full Text] [Related]
11. Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation.
Albrektsen T; Frederiksen KS; Holmes WE; Boel E; Taylor K; Fleckner J
Diabetes; 2002 Apr; 51(4):1042-51. PubMed ID: 11916924
[TBL] [Abstract][Full Text] [Related]
12. Partial agonist, telmisartan, maintains PPARγ serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass.
Kolli V; Stechschulte LA; Dowling AR; Rahman S; Czernik PJ; Lecka-Czernik B
PLoS One; 2014; 9(5):e96323. PubMed ID: 24810249
[TBL] [Abstract][Full Text] [Related]
13. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo.
Lecka-Czernik B; Ackert-Bicknell C; Adamo ML; Marmolejos V; Churchill GA; Shockley KR; Reid IR; Grey A; Rosen CJ
Endocrinology; 2007 Feb; 148(2):903-11. PubMed ID: 17122083
[TBL] [Abstract][Full Text] [Related]
14. Protein Phosphatase PP5 Controls Bone Mass and the Negative Effects of Rosiglitazone on Bone through Reciprocal Regulation of PPARγ (Peroxisome Proliferator-activated Receptor γ) and RUNX2 (Runt-related Transcription Factor 2).
Stechschulte LA; Ge C; Hinds TD; Sanchez ER; Franceschi RT; Lecka-Czernik B
J Biol Chem; 2016 Nov; 291(47):24475-24486. PubMed ID: 27687725
[TBL] [Abstract][Full Text] [Related]
15. INT131: a selective modulator of PPAR gamma.
Motani A; Wang Z; Weiszmann J; McGee LR; Lee G; Liu Q; Staunton J; Fang Z; Fuentes H; Lindstrom M; Liu J; Biermann DH; Jaen J; Walker NP; Learned RM; Chen JL; Li Y
J Mol Biol; 2009 Mar; 386(5):1301-11. PubMed ID: 19452630
[TBL] [Abstract][Full Text] [Related]
16. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells.
Bäckesjö CM; Li Y; Lindgren U; Haldosén LA
J Bone Miner Res; 2006 Jul; 21(7):993-1002. PubMed ID: 16813520
[TBL] [Abstract][Full Text] [Related]
17. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
Fujimura T; Kimura C; Oe T; Takata Y; Sakuma H; Aramori I; Mutoh S
J Pharmacol Exp Ther; 2006 Aug; 318(2):863-71. PubMed ID: 16682454
[TBL] [Abstract][Full Text] [Related]
18. Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice.
Li M; Pan LC; Simmons HA; Li Y; Healy DR; Robinson BS; Ke HZ; Brown TA
Bone; 2006 Oct; 39(4):796-806. PubMed ID: 16759917
[TBL] [Abstract][Full Text] [Related]
19. Mechanical loading down-regulates peroxisome proliferator-activated receptor gamma in bone marrow stromal cells and favors osteoblastogenesis at the expense of adipogenesis.
David V; Martin A; Lafage-Proust MH; Malaval L; Peyroche S; Jones DB; Vico L; Guignandon A
Endocrinology; 2007 May; 148(5):2553-62. PubMed ID: 17317771
[TBL] [Abstract][Full Text] [Related]
20. Regulation of human skeletal stem cells differentiation by Dlk1/Pref-1.
Abdallah BM; Jensen CH; Gutierrez G; Leslie RG; Jensen TG; Kassem M
J Bone Miner Res; 2004 May; 19(5):841-52. PubMed ID: 15068508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
